Cataract Therapeutics

Formosa Pharmaceuticals, AimMax Therapeutics unveiled data from CPN-301, the first of two pivotal Phase 3 clinical studies of APP13007, a novel ophthalmic nanosuspension formulation of a potent corticosteroid, clobetasol propionate (0.05%).

Beginning in the 1970s, James J. Salz, MD, was part of a group of ophthalmologists who first inserted intraocular lens implants during cataract surgery.

The injection of dexamethasone intraocular suspension 9% into the capsular bag may change the standard of care following cataract surgery.

Physicians find the Vivity lens offers their patients reduced glare, halos and increased spectacle independence.

Dr. Rishi Raj Borah, Country Director with Orbis India, discusses recent research he co-authored showing the top 3 barriers keeping families from accessing cataract treatment for their children in India.

Lisa M. Nijm, MD, JD, previews the program for this April 2 virtual event designed to help young ophthalmologists learn everything they need to know when starting practice.

The eye care nonprofit has continually harnessed the power of innovation to reach new heights in the fight against avoidable blindness.

Proper measurement of the eye is key to predicting lens strength.

Lisa Nijm, MD, discusses how utilizing a dexamethasone intracanalicular insert after cataract surgery saves time for practices.

The study reviews the outcomes following penetrating, closed trauma–related injuries.

Research also highlights the top factors that lead to care, which can be used to improve parents' uptake of sight-saving surgery for their children.

According to investigators, patients implanted with diffractive multifocal IOLs had notable declines in the corrected distance visual acuity, distance corrected near VA, and near area of focus with aging